跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TAFINLAR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TAFINLAR
Authorized
STANDARD
TAFINLAR
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7a5a8dee52d6d44e
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
7a5a8dee52d6d44e
Drug Approval Canada Name
TAFINLAR
Product Name
TAFINLAR
Status
Marketed
Status Date
2023-11-30
Original Market Date
2023-11-30
Din
02540053
Drug Class
Human
Dosage Form
Tablet For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EC02 DABRAFENIB
Atc Name
l 01 ec 02
Aig Number
0154510003
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
DABRAFENIB (DABRAFENIB MESYLATE)
10 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7a5a8dee52d6d44e
Type
Standard
Back to Health Canada Approvals